Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-01-29
2000-02-22
Kunz, Gary L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514825, 514886, 4242441, 5361231, A61K 31715, A61K 3909, C07H 100
Patent
active
060280603
ABSTRACT:
A method of treating a chronic inflammatory disease such as rheumatoid arthritis or psoriasis includes treating a patient with a toxin derived from Group B .beta.-hemolytic Streptococcus bacteria. The purified GBS toxin, or CM101, may be administered intravenously to the patient in repeated doses.
REFERENCES:
patent: 4242326 (1980-12-01), Sugawara et al.
patent: 4882317 (1989-11-01), Marbrug et al.
patent: 4895838 (1990-01-01), McCluer et al.
patent: 5010062 (1991-04-01), Hellerqvist et al.
patent: 5225331 (1993-07-01), Jennings et al.
patent: 5302386 (1994-04-01), Kasper et al.
patent: 5382514 (1995-01-01), Passaniti et al.
Kovacs et al., "Fibrogenic cytokines and connective tissue production", FASEB J. for Experimental Biology 8(11):854-861 (1994).
Hellerqvist et al., "Preliminary results of a Phase I trial of CM101 in cancer patients", J. of Cellular Biochemistry, Supp 19B, p. 26 (1995).
Arbiser, J. L., M.D., Ph.D., Angiogenesis and the Skin: A Primer, J. of the American Academy of Dermatology, 34(3):486-497, (1996).
Augustin, H. G., et al., Ovarian Angiogenesis: Phenotypic Characterization of Endothelial Cells in a Physiological Model of Blood Vessel Growth and Regression, Am. J. Pathol., 147(2):339-351, (1995).
Battegay, E. J., Angiogenesis: Mechanistic Insights, Neovascular Diseases, and Therapeutic Prospects, J. Mol. Med., 73:333-346, (1995).
Braverman, I.M., M.D., et al., Role of the Microcirculation in the Treatment and Pathogenesis of Psoriasis, The Journal of Investigative Dermatology, 78(1):12-17, (1982).
Brem, H., et al., Analysis of Experimental Antiagiogenic Therapy, Journal of Pediatic Surgery, 28(3):445-451, (1993).
Brem et al., Time Dependent Suppression of Wound Healing With the Angiogenesis Inhibitor, AGM-1470, J. Cell Biol., 115:403a, (1991).
Brown, L. F., et al., Increased Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Bullous Pemphigoid, Dermatitis Herpetiformis, and Erythema Multiforme, J. Invest. Dermatol., 104(5):744-749, (1995).
Brown, L. F., et al., Overexpression of Vascular Permeability Factor (VPF/VEGF) and its Endothelial Cell Receptors in Delayed Hypersensitivity Skin Reactions, J. Immunol., 154(6):2801-2807, (1995).
Caulfield, J.P., M.D., et al., Morphologic Demonstration of Two Stages in the Development of Type II Collagen-Induced Arthritis, Laboratory Investigation, 46(3):321-343, (1982).
Colville-Nash, P.R., et al., Angiogenesis and Rheumatoid Arthritis: Pathogenic and Rherapeutic Implications, Annals of the Theumatic Diseases, 51:919-925, (1992).
Courtenay, J.S., et al., Immunisation Against Heterologous Type II Collagen Induces Arthritis in Mice, Nature, 283:666-668, (1980).
D'Amato, Robert M.D., Ph.D., Critical Components of the Female Reproductive Pathway are Suppressed by the Angiogenesis Inhibitor AGM-1470, I.B.C. Conference (1996).
Detmar, M., et al., Overexpression of Vascular Permeability Factor/Vascular Endothelial Growth Factor and its Receptors in Psoriasis, J. Exp. Med., 180:1141-1146, (1994).
Dvorak, H. F., et al., Vascular Permeability Factor/Vascular Endothelial Growth Factor, Microvascular Hyperpermeability, and Angiogenesis, Am. J. Pathol., 146(5):1029-1039, (1995).
Dvorak, H. F., et al., Vascular Permability Factor/Vascular Endothelial Growth Factor: An Improtant Mediator of Angiogenesis in Malignancy and Inflammation, Int. Arch. Allergy Immunol., 107:233-235, (1995).
Ferrara, N., The Role of Vascular Endothelial Growth Factor in Pathological Angiognesis, Breast Cancer Res. Treat., 36:127-137, (1995).
Ferrara, N., et al., Vascular Endothelial Growth Factor, a Specific Regulator of Angiogenesis, Curr. Opin. Nephrol. Hypertens., 5(1):35-44, (1996).
Folkman, J., et al., Angiogenic Factors, Science, 235:442-447, (1987).
Folkman, J., Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease, Nature Medicine, 1(1):27-31, (1995).
Folkman, J., Diagnostic and Therapeutic Applications of Angiogenesis Research, C. R. Acad. Sci. Paris, Sciences de la vie, 316:914-918, (1993).
Gordon, D.A., et al., Rheumatoid Arthritis, Clinical Features: Early, Progressive and Late Disease, Rheumatology, 4.1--4.3, Klippel and Dieppe, eds., Mosby, publ., (1994).
Hellerqvist, C.G., et al., CM101 Induces a Complement-Activated Inflammatory Response Targeting Tumor Neovasculature, Proceedings of the American Assoc. for Cancer Research, 37, Abstract #3328, (1996).
Hellerqvist, C.G., et al., Studies on Group B .beta.-Hemolytic Streptococcus I. Isolation and Partial Characterization of an Extra-Cellular Toxin, Pediatr. Res., 12:892-898, (1981).
Hellerqvist, C.G., et al., Antitumor Effects of GBS Toxin: a Polysaccharide Exotoxin From Group B .beta.-Hemolytic Streptococcus, J. Canc. Res. Clin. Oncol., 120:63-70, (1993).
Hellerqvist, C.G., et al., Early Results of a Phase I Trial of CM101 in Cancer Patients, Proceedings of the American Assoc. of Cancer Research Annual Meeting, 36:224, (1995).
Hellerqvist, C.G., et al., Cytokine Production in Cancer Patients Receiving the Anti-Neovascularization Drug CM-101, Proceedings of ASCO, Abstract #1592, vol. 14, (1995).
Herblin, W., et al., Inhibition of Angiogenesis as a Strategy for Tumor Growth Control, Molecular and Chemical Neuropathology, 21:329-336, (1994).
Hirata, S., et al., Inhibition of In Vitro Vascular Endothelial Cell Proliferation and In Vivo Neovascularization by Low-Dose Methotrexate, Arthritis and Rheumatism, 32(9):1065-1073, (1989).
Ingber, D., et al., Synthetic Analogues of Fumagillin that Inhibit Angiogenesis and Suppress Tumour Growth, Nature, 348:555-557, (1990).
Jennings, H. J., et al., Structural Determination and Serology of the Native Polysaccharide Antigen of Type-III Group B Streptococcus, Canadian J. of Biochemistry, 58(2):112-120, (1980).
Kim, K.J., et al., Inhibition of Vascular Edothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth In Vivo, Nature, 362:841-844, (1993).
Kimball, E.S., et al., Angiogenesis in Pannus Formation, Agents and Actions, 34(3/4):329-331, (1991).
Klagsbrun, M., Regulators of Angiogenesis, Annu. Rev. Physiol., 53:217-239, (1991).
Kusaka, M., et al., Potent Anti-Angiogenic Action of AGM-1470: Comparision to the Fumagillin Parent, Biochemical and Biophysical Res. Communications, 174(3):1070-1076, (1991).
Lawrence, R.C., Classification and Epidemiology, Rheumatology, 3.2--3.3, Klippel and Dieppe, eds., Mosby, publ., (1994).
Liote, F., Synovial Angiogenesis, Rev. Prat., 43(17):2239-2245, (1993).
Malhotra, R., et al., Angiogenic Properties of Normal and Psoriatic Skin Associate with Epidermis, Not Dermis, Laboratory Investigation, 61(2):162-165, (1989).
Matsubara, T., et al., Inhibition of Human Endothelial Cell Proliferation In Vitro and Neovascularization In Vivo by D-Penicillamine, J. Clin. Invest., 83:158-167, (1989).
Moses, M. A., et al., Identification of an Inhibitor of Neovascularization From Cartilage, Science, 248:1408-1410, (1990).
Moses, M.A., A Cartilage-derived Inhibitor of Neovascularization and Metalloproteinases, Clin. and Experimental Rheumatology, 11(Suppl. 8) :S67-S69, (1993).
Nickoloff, B.J., et al., Aberrant Production of Interleukin-8 and Thrombospondin-1 Psoriatic Keratinocytes Mediates Angiogenesis, American Journal of Pathology, 144 (4) :820-828, (1994).
Oliver, S.J., et al., Suppression of Collagen-Induced Arthitis Using an Angiogenesis Inhibitor, AGM-1470, and a Microtubule Stabilizer, Taxol, Cellular Immunology, 157:291-299, (1994).
Ondrick, K., Ph.D., et al., Angiogenesis, Clinics in Podiatric Medicine and Surgery, 9(1):185-203, (1992).
Ono, M., et al., Induction of Human Microvascular Endothelial Tubular Morphogenesis by Human Keratinocytes: Involvement of Transforming Growth Factor-.alpha., Biochem. Biophys. Res. Commun., 189(2):601-609, (1992).
Parkinson, D. R., Present Staus of Biological Response Modifiers in Cancer, The Amer. J. of Medicine, 99 (Suppl.6A):54S-56S, (1995).
Peacock, D.J., et al., An Angiogenesis Inhibitor in Combination with Anti-CD5 Mab Suppresses Established Collagen Induced Arthritis Significantly More Than Single Agent Therapy, Arthritis and Rheumatism, 35(9)
Hellerqvist Carl G.
Wamil Barbara D.
Kunz Gary L.
Vanderbilt University
White Everett
LandOfFree
Treatment of chronic inflammatory diseases with CM101/GBS toxin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of chronic inflammatory diseases with CM101/GBS toxin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of chronic inflammatory diseases with CM101/GBS toxin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-520623